Significance of the indicator ‘gender’, for the values of clinical, laboratory and radiographic parameters in patients with hip osteoarthritis.

Table 4: Significance of the indicator ‘gender’, for the values of clinical, laboratory and radiographic parameters in patients with hip osteoarthritis.

Parameter

Median ± IQR

“H”-patterns^#:

“I”-patterns^†:

“A”-patterns^‡:

p^*

(F vs. M)

DD (months) K/L-II (F + M)

10 (7-13)

8 (5-11)

12 (9-13)

8 (5-11)

6 (3-9)

10 (7-13)

6 (3-9)

4 (1-7)

8 (5-11)

< 0.001

DD (months) K/L-III (F + M)

27 (23-31)

24 (20-28)

30 (26-34)

21 (17-25)

18 (14-22)

24 (20-28)

12 (8-16)

9 (5-13)

15 (11-19)

PW (VAS mm.) K/L-II (F + M)

41 (39-42)

38 (37-39)

44 (41-45)

43 (41-45)

40 (38-42)

46 (44-48)

45 (42-48)

42 (40-44)

48 (44-52)

< 0.001

PW (VAS mm.) K/L-III (F + M)

48 (46-50)

45 (43-47)

51 (49-53)

50󠄀 (48-52)

47 (45-49)

53 (51-55)

50 (48-52)

56 (54-58)

F (WOMAC-C) K/L-II (F + M)

32 (30-34)

29 (28-30)

35 (32-38)

34 (32-36)

31 (30-32)

37 (34-40)

37 (35-39)

34 (32-36)

40 (38-42)

< 0.001

F(WOMAC-C) K/L-III (F + M)

38 (36-40)

35 (33-38)

41 (39-42)

41 (39-43)

38 (36-40)

44 (40-46)

43 (41-45)

40 (38-42)

46 (44-48)

s-CTX-I K/L-II (F + M)

520 (460-600)

460 (420-500)

580 (500-700)

590 (510-670)

530 (470-590)

650 (550-750)

650 (600-700)

590 (530-650)

710 (650-780)

< 0.001

s-CTX-I K/L-III (F + M)

561(501-621)

500 (440-560)

620 (560-680)

646 (601-701)

585 (525-645)

705 (675-765)

716 (651-781)

650 (590-710)

780 (710-850)

u-CTX-II K/L-II (F + M)

346 (300-390)

300 (255-345)

392 (345-435)

378 (330-415)

322 (260-380)

436 (376-455)

456 (416-496)

400 (340-460)

520 (470-530)

< 0.001

u-CTX-II K/L-II (F + M)

378 (318-438)

320 (280-360)

460 (360-520)

420 (360-480)

360 (300-420)

480 (420-540)

480 (430-530)

420 (390-450)

540 (470-610)

AP-spine BMD K/L-II (F + M)

1.3 (1.1-1.6)

1.6 (1.4-1.8)

1.0 (0.9-1.4)

1.1 (0.9-1.3)

1.4 (1.2-1.5)

0.8 (0.6-1.1)

0.8 (0.6-0.9)

1.0 (0.9-1.1)

0.6 (0.3-0.7)

< 0.001

AP spine BMD K/L-III (F + M)

1.1 (0.9-1.3)

1.4 (1.2-1.6)

0.8 (0.6-1.0)

1.1 (0.9-1.2)

0.5 (0.3-0.8)

0.6 (0.5-0.7)

0.9 (0.8-1.0)

0.3 (0.2-0.4)

TH-BMD K/L-II (F + M)

0.8 (0.6-1.0)

1.1 (0.8-1.2)

0.5 (0.4-0.8)

0.6 (0.5-0.7)

0.9 (0.8-1.0)

0.3 (0.2-0.4)

0.4 (0.3-0.5)

0.7 (0.5-0.8)

0.1 (0.05-0.2)

< 0.001

TH-BMD K/L-III (F + M)

0.7 (0.6-0.8)

1.0 (0.9-1.1)

0.4 (0.3-0.5)

0.5 (0.4-0.6)

0.8 (0.6-0.9)

0.2 (0.2-0.3)

0.3 (0.2-0.4)

0.5 (0.4-0.6)

0.1 (0.03-0.1)

TB-BMD K/L-II (F + M)

1.5 (1.3-1.7)

1.8 (1.7-1.9)

1.2 (0.9-1.5)

1.4 (1.3-1.5)

1.7 (1.6-1.8)

1.1 (1.0-1.2)

1.3 (1.1-1.5)

1.6 (1.5-1.7)

1.0 (0.7-1.3)

< 0.001

TB-BMD K/L-III (F + M)

1.4 (1.2-1.6)

1.7 (1.6-1.8)

1.1 (1.0-1.2)

1.3 (1.1-1.5)

1.6 (1.5-1.7)

1.0 (0.9-1.1)

1.2 (1.0-1.4)

1.5 (1.4-1.6)

0.9 (0.8-1.0)

JSW (mm.) K/L-II (F + M)

4.5 (4.3-4.7)

4.8 (4.7-4.9)

4.2 (4.0-4.4)

4.4 (4.2-4.6)

4.7 (4.6-4.8)

4.1 (3.9-4.2)

4.3 (4.1-4.4)

4.6 (4.5-4.7)

4.0 (3.7-4.1)

< 0.001

JSW (mm.) K/L-III (F + M)

3.7 (3.5-3.9)

4.0 (3.9-4.1)

3.4 (3.1-3.7)

3.5 (3.3-3.7)

3.8 (3.6-3.9)

3.2 (3.0-3.5)

3.3 (3.2-3.4)

3.6 (3.4-3.8)

3.0 (2.8-3.2)

^#-‘H’ patterns of three groups -N = 150 (K/L-II -75, ♂-30/♀-45; K/L-III -75, ♂-30/♀-45); ^†-‘I’-patterns: N = 150 (K/L-II -75, ♂-30/♀-45; K/L-III -75, ♂-30/♀-45); ^‡-‘A’ -patterns: -N = 100 (K/L-II -50, ♂-20/♀-30; K/L-III -50, ♂-20/♀-30); ^*- All interim comparisons were performed with Kruskal-Wallis test followed by Dunn-Bonferroni post hoc for the final analyses; PW - Pain at walking by VAS; F (WOMAC-C) - WOMAC function scale; mJSW - mean joint space width in millimeters; s-CTX-I - serum CTX-I, the levels are given as nanogram per milliliter; u-CTX-II - Urine-CTX-II the levels are given as ng/mmol Cr; K/L - II/III -radiographic grades according to Kellgren-Lawrence; ‘A’; ‘I’; ‘H’ -radiographic patterns (atrophic /normotrophic /hypertrophic).